These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12422050)

  • 1. HER-targeted tyrosine-kinase inhibitors.
    Baselga J; Hammond LA
    Oncology; 2002; 63 Suppl 1():6-16. PubMed ID: 12422050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular target-based cancer therapy: tyrosine kinase inhibitors.
    Tamura K; Fukuoka M
    Int J Clin Oncol; 2003 Aug; 8(4):207-11. PubMed ID: 12955575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I studies of ZD1839 in patients with common solid tumors.
    Lorusso PM
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib (Tarceva): an update on the clinical trial program.
    Herbst RS
    Semin Oncol; 2003 Jun; 30(3 Suppl 7):34-46. PubMed ID: 12840799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase signal transduction inhibitors. Clinical trials.
    Scagliotti GV
    Suppl Tumori; 2002; 1(4):S34-6. PubMed ID: 12415814
    [No Abstract]   [Full Text] [Related]  

  • 6. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
    Ritter CA; Arteaga CL
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):3-11. PubMed ID: 12644979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
    Bonomi P
    Lung Cancer; 2003 Aug; 41 Suppl 1():S43-8. PubMed ID: 12867061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic implications of epidermal growth factor receptor in lung cancer].
    Fayette J; Le Chevalier T; Soria JC
    Bull Cancer; 2003 Nov; 90 Spec No():S233-40. PubMed ID: 14763145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.
    Van Zandwijk N; Baas P
    Suppl Tumori; 2002; 1(4):S37-8. PubMed ID: 12415815
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
    Krozely P
    Clin J Oncol Nurs; 2004 Apr; 8(2):163-8. PubMed ID: 15108418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
    Slichenmyer WJ; Fry DW
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):67-79. PubMed ID: 11706398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
    Bunn PA; Franklin W
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):38-44. PubMed ID: 12422312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
    Friess T; Scheuer W; Hasmann M
    Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.